convertibleCAR-T cells provide a modular universal system for dose control of activity, flexible targeting, and versatile maintenance of CAR-cells

ABSTRACT Current chimeric antigen receptor (CAR) cellular therapies, while remarkably efficacious, have a number of limitations that impact their efficacy, safety and perseverance in the clinical setting, including commitment to targeting a single antigen, utilization of non-human components, and lack of dose control. We have developed a universal CAR platform to function as a flexible and controllable system to address these limitations. An inert form of the NKG2D extracellular domain (iNKG2D) was used as the surface-exposed portion of the CAR and transduced into T cells to generate convertibleCARTM-T cells. These cells were activated only when an immunological synapse was formed with a displayed antigenic target, mediated by a bispecific molecule comprised of an iNKG2D-exclusive orthogonal human ligand fused to an antigen-targeting antibody (MicAbodyTM). By altering the Fv domains of the MicAbody, cytolytic activity against a variety of antigen-expressing cell lines was demonstrated in vitro. In addition to sequential introduction of MicAbodies, arming convertibleCAR-T cells with a combination of MicAbodies resulted in simultaneous activity against different antigen-containing targets. Additionally, activation and cytolytic functions of convertibleCAR-T cells depended upon the dose of MicAbody introduced. Studies in NSG mice exploring efficacy against Raji tumors demonstrated dose-dependent control of tumor mass by rituximab-based MicAbody as well as by convertibleCAR-T cells. We have also demonstrated that the exclusive ligand-receptor partnering enabled the targeted delivery of ligand-fused payloads to convertibleCAR-T cells. Ligand fusion to CDC-enhanced Fc domains led to in vitro reduction of convertibleCAR-T cells by human complement, thus offering the ability to reduce the levels of CAR cells in a patient without necessarily completely eliminating them. Selective delivery of a mutant IL-2 drove expansion of convertibleCAR-T cells in vitro and promoted in vivo expansion and recovery. This ability to leverage the exclusive ligand-receptor interaction has profound implications for the ability to exogenously control convertibleCAR-T cell expansion, persistence, and function within the patient. This, combined with the ability to switch targets and multiplex without modifying the CAR, enables the development of a highly modular and adaptable universal system to create a single autologous cell for all targets in a single donor patient or one allogeneic cell for all patients and all targets.

[1]  L. Weinberger,et al.  Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform , 2019, Cell.

[2]  D. Powell,et al.  The Emergence of Universal Immune Receptor T Cell Therapy for Cancer , 2019, Front. Oncol..

[3]  M. Brenner,et al.  Chimeric Antigen Receptors for T-Cell Malignancies , 2019, Front. Oncol..

[4]  Elvira Khialeeva,et al.  Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory , 2018, Proceedings of the National Academy of Sciences.

[5]  Alaina Kaiser,et al.  Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. , 2018, Blood.

[6]  V. Seshan,et al.  Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo , 2018, Nature Biotechnology.

[7]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[8]  J. Greenbaum,et al.  Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.

[9]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[10]  F. Locke,et al.  CAR T cell therapy for B-cell lymphomas. , 2018, Best practice & research. Clinical haematology.

[11]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[12]  Yang Feng,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature Medicine.

[13]  E. Wherry,et al.  Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia , 2017 .

[14]  M. Ruella,et al.  Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf , 2017, BioDrugs.

[15]  R. Orentas,et al.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  K. Seidl,et al.  Abstract 602: A novel TGF-β/IL-12R signal conversion platform that protects CAR T cells from TGF-β-mediated immune suppression and concurrently amplifies effector function , 2017 .

[17]  P. Moss,et al.  A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding , 2017, Science Signaling.

[18]  Ying Xiong,et al.  A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines , 2017, Journal of Immunotherapy for Cancer.

[19]  I. Diaconu,et al.  Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  C. Turtle,et al.  Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies , 2017, Drugs.

[21]  R. Brentjens,et al.  IL-18 Secreting CAR T Cells Enhance Cell Persistence, Induce Prolonged B Cell Aplasia and Eradicate CD19+ Tumor Cells without Need for Prior Conditioning , 2016 .

[22]  L. Hurton,et al.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells , 2016, Proceedings of the National Academy of Sciences.

[23]  D. Busch,et al.  Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. , 2016, The Journal of clinical investigation.

[24]  Kole T. Roybal,et al.  Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors , 2016, Cell.

[25]  S. Grupp,et al.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. , 2016, The Journal of clinical investigation.

[26]  D. Fremont,et al.  Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy , 2016, Nature Communications.

[27]  G. Ehninger,et al.  Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts , 2016, Blood Cancer Journal.

[28]  M. Baker,et al.  Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. , 2016, The Journal of clinical investigation.

[29]  L. Cooper,et al.  Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  H. Kiyoi,et al.  A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration , 2016, Cancer Immunology Research.

[31]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[32]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[33]  Russell M. Gordley,et al.  Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors , 2016, Cell.

[34]  D. Maloney,et al.  Accepted Article Preview : Published ahead of advance online publication , 2016 .

[35]  Chan Hyuk Kim,et al.  Versatile strategy for controlling the specificity and activity of engineered T cells , 2016, Proceedings of the National Academy of Sciences.

[36]  Yu Cao,et al.  Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies , 2016, Proceedings of the National Academy of Sciences.

[37]  D. Maloney,et al.  Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.

[38]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[39]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[40]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[41]  Jamie B. Spangler,et al.  Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. , 2015, Immunity.

[42]  T. Marafioti,et al.  A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. , 2014, Blood.

[43]  Dario Campana,et al.  T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. , 2014, Cancer research.

[44]  Raphael Sandaltzopoulos,et al.  Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.

[45]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[46]  H. Reyburn,et al.  Human NKG2D-ligands: cell biology strategies to ensure immune recognition , 2012, Front. Immun..

[47]  R. Fuller,et al.  Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences. , 2011, Cold Spring Harbor protocols.

[48]  S. Riddell,et al.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.

[49]  H. Abken,et al.  IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. , 2011, Cancer research.

[50]  S. Rosenberg,et al.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Andrew B. Caldwell,et al.  Systematic mutation and thermodynamic analysis of central tyrosine pairs in polyspecific NKG2D receptor interactions. , 2011, Molecular immunology.

[52]  M. Wittekind,et al.  Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.

[53]  G. A. Lazar,et al.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.

[54]  T. Stehle,et al.  Structure of the HCMV UL16-MICB Complex Elucidates Select Binding of a Viral Immunoevasin to Diverse NKG2D Ligands , 2010, PLoS pathogens.

[55]  Christian Wiesmann,et al.  Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. , 2009, The Journal of clinical investigation.

[56]  T. Spies.  Regulation of NKG2D ligands: a purposeful but delicate affair , 2008, Nature Immunology.

[57]  Raffi Tonikian,et al.  Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries , 2007, Nature Protocols.

[58]  T. Goldmann,et al.  Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. , 2005, Human gene therapy.

[59]  J. Berzofsky,et al.  Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function , 2005, The Journal of experimental medicine.

[60]  Yannick Jacques,et al.  Identification of an Interleukin-15α Receptor-binding Site on Human Interleukin-15* , 2004, Journal of Biological Chemistry.

[61]  R. Strong,et al.  Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. , 2003, Immunity.

[62]  P. Sun,et al.  Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. , 2001, Immunity.

[63]  Adelheid Cerwenka,et al.  Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.

[64]  H. Stephens.  MICA and MICB genes: can the enigma of their polymorphism be resolved? , 2001, Trends in immunology.

[65]  R. Strong,et al.  Complex structure of the activating immunoreceptor NKG2D and its MHC class I–like ligand MICA , 2001, Nature Immunology.

[66]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[67]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[68]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[69]  P. Stastny,et al.  Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. , 1999, Human immunology.

[70]  S. Bauer,et al.  Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. , 1998, Science.

[71]  L. Lanier.  NK cell receptors. , 1998, Annual review of immunology.

[72]  S. Bahram,et al.  Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[73]  O. Silvennoinen,et al.  Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. , 1994, Science.

[74]  E. Grimm,et al.  Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. , 1993, Cancer research.

[75]  G. Ju,et al.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[76]  F. Bach,et al.  DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells , 1991, The Journal of experimental medicine.